Pfizer vouches safety of long-term inhaled insulin.

by Medindia Content Team on  June 11, 2006 at 2:50 PM Drug News   - G J E 4
Pfizer vouches safety of long-term inhaled insulin.
Los Angeles: Pfizer has indicated that recent clinical trials of inhaled insulin has received the approval from the drug regulators and is found to be useful in regulating blood sugar levels spanning a 2 year period.

This product, named Exubera, is slated to be introduced into the United States market soon after the U.S. Food and Drug Administration approves it for use in adults with Type 1 or Type 2 diabetes.

Dr. Julio Rosenstock, trial investigator and director of the Dallas Diabetes & Endocrine Center said "There are a lot of physical barriers to injected insulin. This (Exubera) is a good tool to facilitate initiation of insulin treatment."

For those sufferings Type 2 diabetes, Exubera is permissible either alone or in combination with diabetes medication or longer-acting insulin. For type 1 diabetics, Exubera is advised to be combined with longer-acting insulin. This drug is not to be consumed by smokers, patients with lung problems and expecting women.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All

More News on: